# Product Specification Sheet

**Product Name:** NVP-AUY954  
**Catalog Number:** C6295

## Technical Information:

<table>
<thead>
<tr>
<th><strong>Chemical Formula:</strong></th>
<th>C\textsubscript{25}H\textsubscript{20}F\textsubscript{3}N\textsubscript{2}O\textsubscript{2}S</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAS #:</strong></td>
<td>820240-77-5</td>
</tr>
<tr>
<td><strong>Molecular Weight:</strong></td>
<td>455.12</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt; 99%</td>
</tr>
<tr>
<td><strong>Appearance:</strong></td>
<td>White solid</td>
</tr>
<tr>
<td><strong>Solubility:</strong></td>
<td>Soluble in DMSO up to 50 mM</td>
</tr>
<tr>
<td><strong>Chemical Name:</strong></td>
<td>3-[[2-[4-phenyl-3-(trifluoromethyl)phenyl]-1-benzo thiophen-5-yl]methylamino]propanoic acid</td>
</tr>
</tbody>
</table>

**Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.  
**Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

## Handling:

- To make 10 mM stock solution, add 0.22 mL of DMSO for each mg of NVP-AUY954.
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

## Biological Activity:

NVP-AUY954 is an orally-available, benzothiazole-based, monoselective agonist of the sphingosine-1-phosphate receptor 1 (S1P1) intended for the treatment of human autoimmune mediated inflammatory neuropathies. Along with EC50 potency of 1.2 nM, NVP-AUY954 has at least 280-fold selectivity for S1P1 compared to the receptor's four other subtypes. (1, 2)

NVP-AUY954 induces a potent and reversible reduction of circulating lymphocytes; in combination with Everolimus, NVP-AUY954 can prolong the survival of cardiac allografts in a rat transplantation model. NVP-AUY954 also has been shown to activate downstream kinase cascades, increasing Erk (Tyr204) and Akt (Ser473) phosphorylation at EC50s of 0.1 and 1.0 nM, respectively. (2)

NVP-AUY954 efficacy has been correlated with an accumulation of plasmacytoid dendritic cells (pDC), which may have therapeutic value in the treatment of multiple sclerosis. (3)

## Reference:


For Technical Support: technical@cellagentech.com

*Chemicals are sold for research use only, not for clinical or diagnostic use.*